Of these signatures, Knudsen et al. (20) and Malorni et al. (19), both of which were designed for predicting palbociclib resistance, shared 17 genes each with RBNSig-BC including 11 genes (KIF2C, RAD54L, KIFC1, ORC1, CDCA8, CDC45, FAM83D, CDC20, CENPA, RRM2, and PIF1) that were present in all three signatures. This evidence concerns the gene KIF2C and breast cancer.